跳至主要内容
临床试验/JPRN-UMIN000005248
JPRN-UMIN000005248已完成2 期

WT1 peptide-based cancer vaccine combined with gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a randomised, multicenter, phase 2 clinical study - Advanced pancreatic cancer GEM+WT1 vaccine RCT P2

Department of Cancer Immunotherapy, Osaka university Graduate school of Medicine0 个研究点目标入组 150 人开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Simultaneous or metachronous (within 5 years) double cancers, with exception of intramucosal tumor curable with local therapy 2) Pregnant or lactating women or women fo childearing potential, and men who want to get partner pregnat 3) Psychosis 4) Patients requiring systemic immunosuppresive agents, or moderate or higher dose of steroid with exception of usage for cancer pain 5) Pulmonary fibrosis or interstitial pneumonitis 6) Active bacterial or fungal infection 7) Severe complications 8) MDS, MDS/MPD, MPD 9) Severe drug allergy 10) Inadequate physical condition, as diagnosed by the primary physician

研究者

发起方
Department of Cancer Immunotherapy, Osaka university Graduate school of Medicine

相似试验